000			05354cam a2200397Ii 4500
001			95511
003			ES-MaUEC
005			20230102112707.0
006			m o d
007			cr cnu|||unuuu
008			170306s2017 si o 000 0 eng d
020			_a9789811033490 _q(electronic bk.)
020			_a9811033498 _q(electronic bk.)
020			_z9789811033483 _q(print)
020			_z981103348X
040			_aN$T _cN$T _dGW5XE _dIDEBK _dEBLCP _dN$T _dYDX _dOCLCF _dNJR _dDKU _dIOG _dCOO _dAZU _dUPM _dMERER _dESU _dOCLCQ _dJBG _dIAD _dICW _dICN _dOTZ _dVT2 _dOCLCQ _dU3W _dES-MaUEC _bspa
050		4	_aRC270.3.D53 _b2017 EB
066			_c(S
245	0	0	_aPersonalized pathway-activated systems imaging in oncology : _bprincipal and instrumentation _cTomio Inoue, David Yang, Gang Huang, editors.
264		1	_aSingapore _bSpringer International Publishing _c2017
300			_a1 recurso en línea
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_6880-01 _aPart 1: Chemical Biology Aspect -- Chapter 1: PET Radiotracers for Tumor Imaging (Ming Rong Zhang) -- Chapter 2. Theranostic tracers for pathway-activated systems in oncology (Lan V. Pham, Jerry L. Bryant, David Yang, and Richard J. Ford) -- Chapter 3. Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP (Chih-Hao K. Kao) -- Part 2: Engineering and Instrumentation Aspect -- Chapter 4. OpenPET enabling PET imaging during radiotherapy (Taiga Yamaya and Hideaki Tashima) -- Chapter 5. High Resolution PET/CT development (Wai-Hoi Wong, and Yuxuan Zhang) -- Part 3: Social Aspect -- Chapter 6. Ethics, Regulations and Clinical Development of Precision Medicine: Activating with molecular imaging (Chieko Kurihara, and Tomio Inoue) -- Chapter 7. Optical Imaging: How far can we go (Wenbin Ma, Sara Herrera-Rodriguez, and Hector Martinez-Valdez) -- Part 4: Clinic Aspect -- Chapter 8. Applications of UIH High Resolution PET/CT in Zhongshan Hospital (Jun Zhou, Hongcheng Shi) -- Chapter 9. Clinical evaluation of focused high-resolution breast PET (Kanae Kawai Miyake, Yuji Nakamoto) -- Chapter 10. Recent Developments with Large-bore PET/CT (Tomohiro Kaneta, Tomio Inoue) -- Chapter 11. Copper-labeled radiopharmaceuticals in oncology (Hiroaki Kurihara) -- Chapter 12. PET radiopharmaceuticals in oncology beyond FDG (Shao-Li Song, Pan-Li Li, Gang Huang) -- Chapter 13. Molecular Imaging in Oncology: Challenges and Opportunities in 21st Century (Ya-Ming Li, Ya-Ming Li, David J. Yang, and Xue-Na Li) -- Chapter 14. Visualization of Apoptosis: Annexin V imaging (Skye Hsin-Hsien Yeh, Fan-Lin Kong, Ming-Hsien Lin).
520	3		_aThis comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientistsℓ́ℓmolecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.
650		7	_aCancer _xImaging. _2fast _0(OCoLC)fst00845381 _9139308 _0comprobar BNE19900970859
700	1		_aHuang, Gang, _eeditor literario
700	1		_aInoue, Tomio, _eeditor literario
700	1		_aYang, David, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-981-10-3349-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
880	0		_6505-01/(S _aForeword; Preface; Acknowledgments; Contents; Part I: Chemical Biology Aspect; Chapter 1: PET Radiotracers for€Tumor Imaging; 1.1 Introduction; 1.2 [18F]FDG for€Glucose Metabolism; 1.3 Amino Acids; 1.4 Nucleic Acids; 1.5 Lipid Metabolism; 1.6 Hypoxia; 1.7 Receptor and€Angiogenesis; 1.7.1 Somatostatin Receptors; 1.7.2 Integrin Receptor Subtype αvβ3; 1.7.3 Other Receptors Involved in€Tumor Angiogenesis; 1.8 Metabotropic Glutamate 1 Receptor; 1.9 Summary; References; Chapter 2: Theranostic Approaches for€Pathway-ƯActivated Systems in€Oncology; 2.1 Diffuse Large B-Cell Lymphoma Pathophysiology.
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95511 _d95511 _x1